Navigation Links
New Data Presented on Micardis (Telmisartan) Tablets in,Hypertensive Patients With Type 2 Diabetes

observational studies investigating the effects of Micardis (telmisartan) compared with other treatments, including other available ARBs, for hypertension. Note that these trials were investigational and were conducted to expand scientific knowledge of Micardis (telmisartan). These trials include treatment for conditions outside of the approved indications for Micardis (telmisartan).

*A prospective, randomised, double-blind, double-dummy, forced-titration, multicenter, parallel group, 1-year treatment trial to compare telMisartan 40 mg titrated to 80 mg versus losArtan 50 mg titrated to 100 mg, in hypertensive type 2 DiabEtic patients with Overt nephropathy.

About Micardis(R) (telmisartan) tablets

MICARDIS is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension and may be used alone or in combination with other antihypertensive agents. In the clinical trial programs PROTECTION, ONTARGET and PRoFESS, over 58,000 patients have been enrolled to investigate the cardiovascular protective effects of MICARDIS.

For more information and full prescribing information, please visit www.MICARDIS.com


    Safety Information

USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, MICARDIS Tablets should be discontinued as soon as possible (see WARNINGS, Fetal/Neonatal Morbidity and Mortality).

MICARDIS is indicated for the treatment of hypertension.

MICARDIS is contraindicated in patients who are hypersensitive to any of its components.

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those receiving high doses of diuretics), symptomatic hypotension may occur after initiation of MICARDIS therapy.
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo
Post Your Comments:
Breaking Medicine Technology:FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3More Preemies Born Among the Poor 62390 1More Preemies Born Among the Poor 62390 2ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 62385 1ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 62385 2ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 62385 3Rate of Confirmed AIDS in Prison 2 5 Times the Rate in the U S General Population 62380 1Rate of Confirmed AIDS in Prison 2 5 Times the Rate in the U S General Population 62380 2Rate of Confirmed AIDS in Prison 2 5 Times the Rate in the U S General Population 62380 3